Keap1-Nrf2-IN-14
Based on 1 publication(s) in Google Scholar
Keap1-Nrf2-IN-14 (compound 20c) is a KEAP1-NRF2 inhibitor that effectively disrupts the KEAP1-NRF2 interaction (IC50=75 nM) with a Kd value of 24 nM for KEAP1. Keap1-Nrf2-IN-14 induces the expression of NRF2 target genes and enhances the downstream antioxidant and anti-inflammatory activities. Keap1-Nrf2-IN-14 can be used in the study of oxidative stress-related inflammation.
For research use only. We do not sell to patients.
- Purity: 98.08%
- CAS No.: 1928782-31-3
- Formula: C30H29NO8S
- Molecular Weight:563.62
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Keap1-Nrf2-IN-14
More
Biological Activity
|
KEAP1-NRF2 75 nM (IC50) |
Keap1-Nrf2-IN-14 effectively activated NRF2-ARE regulated cytoprotective defense system in both concentration- and time- dependent manner in RAW264.7 cells[1].
Keap1-Nrf2-IN-14 (1, 10 µM; 12 h) enhanced the antioxidant capacity in macrophage RAW 264.7 cells[1].
Keap1-Nrf2-IN-14 (1, 10 µM; 12 h) attenuates LPS-induced production of inflammation factors in RAW 264.7 cells[1].
Keap1-Nrf2-IN-14 shows high metabolic stability (in co-incubation with rat liver microsomes with half-life of 10.5 h), and have no CYP inhibition on 1A2, 2C9, 2C19, 2D6 and 3A4 when at 10 µM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells (LPS-stimulated)
-
Concentration:10 µM
-
Incubation Time:12 h
-
Result:Significantly reduced ROS generation to nearly normal level.
-
Cell Line:RAW264.7 cells (LPS-stimulated)
-
Concentration:1, 10 µM
-
Incubation Time:12 h
-
Result:Notably restored the SOD and GSH-Px levels.
Markedly attenuated the levels of the inflammatory factors IL-1b, IL-6, TNF-a and NO (induced by LPS) in a concentration-dependent manner, and when at 10 µM, almost reduced these cytokines to the basal level.
-
Cell Line:RAW264.7 cells
-
Concentration:0.1, 1, 5, 10 µM
-
Incubation Time:12 h
-
Result:Strongly increased the transcription of NRF2 regulated genes in RAW264.7 cells at a concentration-dependent manner.
-
Cell Line:RAW264.7 cells
-
Concentration:10 µM
-
Incubation Time:1, 2, 4, 8, 16, 24 h
-
Result:Led to nuclear translocation of NRF2 began within 2 h, maximized at 8 h and subsequently declined after 16 h.
Induced NRF2, HO-1, NQO-1 and GCLM protein expression in a time- dependent manner.
Keap1-Nrf2-IN-14 (1 mg/kg; i.v.; single) shows half-life of 1.72 h in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6 mice (18-22 g; LPS-induced inflammation model)[1].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; single daily for 3 days.
-
Result:Diminished LPS-induced inflammatory response in vivo.
-
Animal Model:Female C57BL/6 mice (18-22 g; LPS-induced inflammation model)[1].
-
Dosage:1 mg/kg
-
Administration:Intravenous injection; single.
-
Result:Led to half-life of 1.72 h.
Chemical Information
-
CAS No. 1928782-31-3
-
Appearance Solid
-
Molecular Weight 563.62
-
Formula C30H29NO8S
-
Color Gray to brown
-
SMILES
O=C(O)C(OC1=C2C=CC=CC2=C(N(CC(O)=O)S(=O)(C3=C(C)C=C(C)C=C3C)=O)C=C1)C4=CC=C(OC)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Front Vet Sci
Exploration of the protective mechanisms of Icariin against cisplatin-induced renal cell damage in canines. [Abstract]2024 Feb 21:11:1331409. PMID: 38455257
Solvent & Solubility
DMSO : 100 mg/mL (177.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7742 mL | 8.8712 mL | 17.7425 mL | 44.3561 mL |
| 5 mM | 0.3548 mL | 1.7742 mL | 3.5485 mL | 8.8712 mL | |
| 10 mM | 0.1774 mL | 0.8871 mL | 1.7742 mL | 4.4356 mL | |
| 15 mM | 0.1183 mL | 0.5914 mL | 1.1828 mL | 2.9571 mL | |
| 20 mM | 0.0887 mL | 0.4436 mL | 0.8871 mL | 2.2178 mL | |
| 25 mM | 0.0710 mL | 0.3548 mL | 0.7097 mL | 1.7742 mL | |
| 30 mM | 0.0591 mL | 0.2957 mL | 0.5914 mL | 1.4785 mL | |
| 40 mM | 0.0444 mL | 0.2218 mL | 0.4436 mL | 1.1089 mL | |
| 50 mM | 0.0355 mL | 0.1774 mL | 0.3548 mL | 0.8871 mL | |
| 60 mM | 0.0296 mL | 0.1479 mL | 0.2957 mL | 0.7393 mL | |
| 80 mM | 0.0222 mL | 0.1109 mL | 0.2218 mL | 0.5545 mL | |
| 100 mM | 0.0177 mL | 0.0887 mL | 0.1774 mL | 0.4436 mL |
Keap1-Nrf2-IN-14 Related Classifications
HY-151362 Related Classifications
Powered by Bioz